GRAPHICAL ABSTRACT
Asthma, a chronic inflammatory airway disease characterized by variable airflow obstruction and airway hyperresponsiveness, affects about 300 million persons worldwide, with increasing incidence and prevalence in many developing countries. An especially huge burden on affected subjects and health care systems is brought by asthma exacerbations, frequently requiring emergency treatment or hospitalization. 1, 2 Asthma exacerbations are most frequently triggered by viral respiratory tract infections, especially with human rhinoviruses (RVs). Respiratory viruses can be detected in about 80% of children and in at least 50% of adults experiencing asthma exacerbations. Comprising approximately 65% of these, RVs represent the major cause of asthma exacerbations. [2] [3] [4] [5] In addition, viral respiratory tract infections, especially with RVs, are a major (>50%) trigger of exacerbations also in patients with chronic obstructive pulmonary disease (COPD). 6 Finally, RVs cause more than 50% of common cold cases associated with impaired quality of life and absences from job or school. 7 RVs are classified into 3 species (A, B, and C) of enteroviruses in the Picornaviridae family. The RV-As and RV-Cs are more clinically important because they tend to cause more severe illnesses in children compared with RV-Bs. [8] [9] [10] [11] [12] [13] Despite the obvious medical need, no drug directly targeting RV infection is clinically available. Several factors could have made it difficult to develop a universal anti-RV drug or vaccine, such as a large (and still increasing) number of RV strains with rather uniform geographic distribution and high-level betweenstrain sequence variability. 7, 14 Considering that RVs possess positive-sense single-stranded RNA as their genome, 7, 15, 16 they might represent an ideal target for DNAzymes, a novel antisense-based treatment modality, which specifically bind and then degrade RNA target molecules through enzymatic cleavage. [17] [18] [19] As a proof of concept, recently, an anti-GATA3 DNAzyme has been shown to be clinically safe and effective in patients with allergic asthma. [18] [19] [20] [21] [22] [23] Here we report the successful development and in vitro and ex vivo efficiency of DNAzyme candidates specifically targeting almost all known RV strains.
METHODS

In vitro and in silico testing
Plasmids. Genomic RNAwas isolated from RVA1, RVA16, and RVA29 by using the QIAamp UltraSens Virus Kit (Qiagen, Hilden, Germany). cDNA was synthesized with the Omniscript RT Kit (Qiagen), with addition of the RNaseOUT Recombinant Ribonuclease Inhibitor (Thermo Fisher Scientific, Waltham, Mass). Cloning inserts corresponding to 59-untranslated region (UTR) and cis-acting replication element (CRE; Fig 1) 24-26 sequences were amplified by using the HotStarTaq Master Mix Kit (Qiagen), and primers were listed in Table E1 in this article's Online Repository at www.jacionline.org. PCR products were subjected to 0.8% agarose/TBE buffer gel electrophoresis, extracted with the QIAquick Gel Extraction Kit (Qiagen), and integrated into an RNA-expressing plasmid (pGEM-T Easy Vector Systems; Promega, Madison, Wis). Ligation products were used to transform JM109 High Efficiency Competent Cells (Promega). After a short cultivation in SOC medium (Promega), bacteria were transferred onto LB Agar plates with addition of 100 mg/mL ampicillin and cultured overnight. Positive cultures were transferred from the plate to 4-mL cultures (LB Broth, 100 mg/mL ampicillin) and cultured overnight. Plasmid DNA was isolated with the QIAprep Spin Miniprep Kit (Qiagen), and cloning success was tested through EcoRI (FastDigest EcoRI; Thermo Fisher Scientific) digestion, 1.5% agarose/TBE buffer gel electrophoresis, and plasmid insert sequencing (Seqlab, G€ ottingen, Germany) with the standard SP6 primer. Clones containing the desired sequence were expanded overnight in 4-mL cultures (LB Broth, 100 mg/mL ampicillin) before plasmid DNA was isolated with the HiSpeed Plasmid Maxi Kit (Qiagen).
RNA synthesis. Plasmids were linearized by means of NcoI (RVA29 CRE) or SpeI (all the others; both enzymes purchased from Thermo Fisher Scientific) restriction. Reaction products were subjected to EDTA/NH 4 Ac/ ethanol precipitation. Successful linearization was controlled by using 0.8% agarose/TBE buffer gel electrophoresis. In vitro transcription was conducted with the Ambion MEGAscript SP6 (RVA29 CRE) or T7 (the remainders) Transcription Kits (both from Thermo Fisher Scientific). Synthesized RNAs were purified with the RNeasy Mini Kit (Qiagen).
DNAzyme candidates. DNAzymes of the 10-23 family, which are characterized by the constant 15-nucleotide central catalytic core sequence 59-GGCTAGCTACAACGA-39 and 2 target-specific binding domains, were generated. 21, 22, [27] [28] [29] For the screening phase, candidate DNAzymes with 9-nucleotide binding arms were designed against every GU site in the cloned viral RNA fragments. Sequences of all those DNAzyme candidates are available on request. In later steps molecules with shorter or longer binding domains were also developed. Candidate anti-RV (Dua-01-L12R9, 59-gaaacacggacaGGCTAGCTACAA CGAccaaagtag-39; Dua-02-L10R11, 59-gaaacacggaGGCTAGCTACAACGA acccaaagtag-39) and scrambled control DNAzymes (RANDOM O, 59-aga ggccgaGGCTAGCTACAACGAtcgctatac-39; RANDOM 2, 59-aagcgacgaa GGCTAGCTACAACGAaacggaatcac-39) were modified by attachment of an inverted thymidine at the 39 end to confer exonuclease protection for ex vivo testing in biological systems. 17, 30, 31 All candidate and control DNAzymes tested in this study were synthesized by Biospring GmbH (Frankfurt, Germany).
Cleavage assay. Candidate DNAzymes were tested for cleaving activity by incubating them with in vitro-transcribed viral RNA sequences for 60 minutes at 378C in reaction buffer (50 mmol/L TRIS-HCl [pH 7.4], 0.1 mol/L NaCl, and 1 mmol/L MgCl 2 ). 21 The reaction was stopped by adding 5 mL of Gel Loading Buffer II (Thermo Fisher Scientific) and incubation for 10 minutes at 658C. Samples were then separated by using 2.5% agarose/TAE buffer gel electrophoresis. Gel pictures were obtained with the Fusion FX7 imaging system (Vilber Lourmat, Eberhardzell, Germany). They were subjected to semiquantitative or quantitative analysis, the latter conducted with LabImage 1D software (Kapelan Bio-Imaging, Leipzig, Germany).
Viral genome databank and in silico strain coverage testing. Full-genome sequences of all RV-type RV genomic sequences reported by McIntyre et al 14 were downloaded from the National Center for Biotechnology Information GenBank database. 32 Genome sequences representing 137 RV types (322 sequences) were retrieved, including 76 RV-A types (197 sequences), 30 RV-B types (68 sequences), and 31 RV-C types (57 sequences). Candidate DNAzymes showing any activity in cleavage assays were in silico tested for coverage (100% reverse complementary sequence match requirement) of the 322 RV sequences by using Clustal Omega software (https://www.ebi.ac.uk/Tools/msa/clustalo/).
Exclusion of cytotoxic and off-target effects
To test for potential murine Toll-like receptor 9 (TLR9)-mediated activation, human embryonic kidney HEK293 cells stably transfected with a murine TLR9 expression plasmid and a nuclear factor kB (NF-kB)-luciferase reporter (kindly provided by Dr S. Bauer, Institute of Immunology, PhilippsUniversity Marburg, Marburg, Germany) 33 were seeded on day 0 at 20,000 cells/well in 96-well mClear microplates (Greiner Bio-One, Frickenhausen, Germany) in 100 mL of Dulbecco modified Eagle medium (DMEM) with 10% FCS, 1% sodium pyruvate, and 1% antibiotic-antimycotic. 22 Seven hours later, 20 mL of dilution rows of candidate DNAzymes or reference oligonucleotides, with the latter known to stimulate mouse or human TLR9 (ODN 1668 and ODN 2006, respectively; InvivoGen, San Diego, Calif) were added to final concentrations ranging from 30 mmol/L down to 120 nmol/L. Twenty hours after treatment, 10 mL of CellTiter-Blue Cell Viability Assay (Promega) reagent was added, and cells were incubated again for 3 hours with untreated cells served as control. After CellTiter-Blue measurement, medium was removed, 75 mL of ONE-Glo Luciferase Assay System (Promega) reagent was added, and luminescence was measured as a parameter for NF-kB activation. Similar procedures were applied to test human TLR9 activation, except that HEK-Blue hTLR9 cells and QUANTIBlue assay were used (both from InvivoGen). 
Antiviral efficacy testing in living cells
Organization of the RV genome with secondary structure and cleavage sites of active DNAzyme candidates in the 59-UTR. RVs possess positive-sense single-stranded RNA as their genome, which comprises 2 noncoding regions (59-UTR and -39-UTR) and a single open reading frame (ORF) subdivided into parts according to the 11 proteins formed after the translated polyprotein is processed. Additionally, the cis-acting replication element (CRE; marked by #) is localized at different positions in the ORF depending on RV classification: 2A for RV-A, VP1 for RV-B (putative CRE predicted in 2C of RV-B is not functional; brackets but not boldface), and possibly VP2 for RV-C. 25, 26 At the 59-end, the small protein VPg, which is important for initiation of replication, is fixed to the genomic RNA, whereas the 39-terminus ends with a poly(A) sequence. The 59-UTR contains 2 conserved sections: the characteristic cloverleaf structure (CL) and the internal ribosomal entry site (IRES), the latter with multiple stem-loop structures (as exemplified by RV-2 sequence; modified from Anderson et al 24 ). Cleavage sites for Dua-1 and Dua-2 are indicated and underlined.
J ALLERGY CLIN IMMUNOL VOLUME 143, NUMBER 4 plates, and when they reached 70% to 80% confluence, complete medium was replaced with starvation medium (DMEM with 4% FBS) and incubated for 16 hours before infection. For infection, cells were incubated with 1 multiplicity of infection of RVA1, RVA16, or RVA29 or control medium (HeLa lysate) for 1 hour with gentle shaking. Virus/control solution was then removed, and the cells were washed twice with PBS. For transfection, 0.5 mg of candidate or control DNAzyme, 100 mL of DMEM, and 2 mL of HiPerFect Transfection Reagent (Qiagen) were incubated for 10 minutes at room temperature to allow formation of transfection complexes. Afterward, this mixture, along with an additional 200 mL of DMEM, was added onto the cells for 3 hours of incubation (338C in a 5% CO 2 atmosphere. DMEM was then replaced with complete medium, and cells were cultured for another 48 hours. Thereafter, cell supernatants were collected and centrifuged at 2000g for 5 minutes to remove cell debris. Viral titers in supernatants were determined by using the 50% tissue culture infective dose (TCID 50 ) method with Ohio HeLa cells, as described previously. [34] [35] [36] Nasal polyp tissue. Sinonasal tissue was obtained from 6 patients with chronic rhinosinusitis with nasal polyps (CRSwNP) undergoing routine operations at the Department of Otorhinolaryngology, Ghent University Hospital, Ghent, Belgium. None of the patients had taken oral corticosteroids or antibiotics 4 weeks and topical corticosteroids 2 weeks before surgery. The diagnosis of CRSwNP was made according to European Position Paper on Rhinosinusitis and Nasal Polyps 2012 (EPOS2012) guidelines. 37 The Ethics Committee of Ghent University Hospital approved the study, and informed consent was obtained from all patients before sample collection. Sinonasal tissues were washed 3 times with tissue culture medium (TCM) composed of RPMI 1640 and DMEM (1:1) with 50 IU/mL penicillin and 50 mg/mL streptomycin (all from Thermo Fisher Scientific) and cut into 10 small cubes approximately 25 mm 3 in size. 38, 39 According to results of preliminary experiments, each cube was infected separately with 1 mL of inoculum containing 1 3 10 7 TCID 50 /mL RVA16 for 12 hours (378C in a 5% CO 2 atmosphere). Afterward, all tissue cubes were washed 3 times with PBS, transferred onto sterile fine-meshed gauze, and incubated (378C in a 5% CO 2 atmosphere) in a 6-well tissue-culture plate for 24 hours under air-liquid interface (ALI) culture conditions with either TCM alone (negative control) or addition of 10 mL (4 mg/mL) of candidate anti-RV or scrambled control DNAzymes on the top of the tissue cube. 20 After 8 hours, another 10 mL (4 mg/mL) of the respective DNAzyme was added on top of the respective tissue cubes. Twenty-four hours from first DNAzyme application, ALI cultures were terminated, and all tissue cubes were snap-frozen until RNA isolation, the latter conducted with the RNeasy Mini Kit (Qiagen). Random Primers (Promega) and the Omniscript RT Kit (Qiagen) were used for cDNA synthesis. The copy number of RVA16 was quantified by using real-time PCR with previously described primers/probes 40 and 2x QuantiTect Probe PCR Master Mix (Qiagen) conducted on the LightCycler 480 Instrument II (Roche Applied Science, Penzberg, Germany). PCR reactions (25 mL) contained 2 mL of cDNA, 50 nmol/L forward RV primer, 300 nmol/L reverse RV primer, 100 nmol/L RV probe, 300 nmol/L 18S rRNA primers, and 100 nmol/L 18S rRNA probe. Copy numbers were determined by using standard curves and normalized with 18S rRNA, a housekeeping gene, used as an internal control. 40 DNAzyme transfection/tissue penetration efficiency was verified in the antiviral efficiency testing cell/tissue experiments by using fluorescently (FAM) labeled unrelated DNAzyme (hgd40) and fluorescence/confocal laser scanning microscopy. 18, 20, 23 
RESULTS
Molecular development of anti-RV DNAzyme candidates
To optimally meet requirements for clinical application, potential anti-RV drug candidates should ideally combine the 2 essential properties of (1) efficient reduction of virus replication and (2) capability of targeting (almost) all known RV strains, the latter because there is no clear geographic distribution of RV strains 14 and no methods available for rapid identification of individual RV types. DNAzymes potentially offer both features through their capacity of strong site-specific cleavage of (in this case genomic viral) RNA [18] [19] [20] [21] [22] [23] and the ability to target multiple RV types at once based on the high between-strain homology of certain regions in the RV genome, 15, 25 respectively. Screening phase. Initially, a screening for molecules showing any catalytic activity against RV genomic sequences of 2 regions predicted by us to be sufficiently highly homologous between the RV strains 59-UTR and CRE was performed. 15, 25, 41 Three widely experimentally used test RV strains were selected, namely RVA1, RVA16, and RVA29. 59-UTR and CRE regions of the 3 selected strains were cloned into RNA expression plasmids, and partial 59-UTR or CRE viral RNA sequences were produced in vitro (Fig 1) . In parallel, all possible DNAzyme candidates against all potential GU cleavage sites localized in those regions were designed and synthesized, including 34 DNAzymes for 59-UTR of RVA1, 42 for 59-UTR of RVA16, 33 for 59-UTR of RVA29, 44 for CRE of RVA1, 41 for CRE of RVA16, and 32 for CRE of RVA29.
All DNAzyme candidates were tested in a cleavage assay, a highly stable and reproducible in vitro method in which target RNA (in this case in vitro transcribed RV 59-UTR or CRE RNA) is incubated in the presence of candidate DNAzymes by using cell cytosol simulating buffer conditions. 21 Then the reaction mixture was separated by means of gel electrophoresis to visualize eventual disappearance of the RNA substrate and resulting appearance of the cleavage products based on their length. 21 Example results from this screening procedure are shown in Fig E1 in this article' s Online Repository at www.jacionline.org. Such candidate DNAzymes demonstrating any catalytic activity in cleavage assays were in silico aligned with genomic sequences of 322 published RV genomic sequences 14 to check for level of reverse complementary sequence match and predict RV strain coverage.
Interestingly, although the vast majority of DNAzyme candidates against 59-UTR (except for Du1B-25) demonstrated only limited enzymatic efficiency (Table I) , some of those targeting the CRE region turned out to be reasonably efficient in their cleavage of viral RNA (Table II) . Vice versa, DNAzymes designed for 59-UTR showed generally much better in silico coverage of RV types than those against CRE (Tables I and II; and see Tables E2  and E3 in this article's Online Repository at www.jacionline. org.), probably because of a rather structural and only limited intraspecies sequence conservation of CRE, which turned out to be not sufficient for our purposes. 25, 41 Two of them, namely Dua-1 and Dua-2, fully matched even more than 98% of currently known RV sequences (Table I and Table E2 ). Interestingly enough, Dua-01 and Dua-02 target one of the most conserved motifs in RV 59-UTR, which is therefore already widely used in molecular diagnostics assays for universal PCR primers. [42] [43] [44] [45] [46] [47] This could be of importance for our study because some of the primers used in those assays and partly overlapping with human genomic DNA from chromosome 6 (human long noncoding RNAB2; GenBank accession no. GQ497714) could produce additional nonspecific amplification products from that region. 11, 45, 47 However, bioinformatics analysis excluded the possibility of an interaction between our DNAzyme candidates Dua-01 or Dua-02 and the human long noncoding RNAB2 mRNA sequence.
Optimization of the most promising candidates. As a result of the screening phase, no single molecule was identified showing both strong enzymatic activity and broad coverage of RV strains. Two possible options were considered for further development (ie, either expanding limited strain coverage of strongly cleaving DNAzyme candidates or enhancing weak enzymatic activity of the molecules fully matching multiple RV types). While the first option was expected to be difficult to achieve, the second approach was pursued further.
For this purpose, a unique molecular modification strategy was applied to the 2 candidate DNAzymes with the highest in silico coverage of known RV strains (ie, Dua-1 and Dua-2). It turned out that the cleavage sites of Dua-1 and Dua-2 have a unique location; that is, they are positioned close to the base in one of the loops present in the 59-UTR of the RV RNA genome (Fig 1) . 24 Such loops are formed because of asymmetric double-stranded parts in the RNA sequence and thus represent areas with rather poor accessibility for DNAzyme binding and cleavage. This might explain the only weak cleavage activity of Dua-1 and Dua-2 DNAzyme candidates observed in the screening phase. We speculated that the binding domains of the 2 candidate DNAzymes were too short to effectively compete with the natural double-strand-forming reverse complementary RNA sequences in this area and thus could not provide sufficient thermodynamic stability of the required RNA-DNA duplex. Thus their left (39) binding domains were lengthened as much as possible without a substantial decrease in in silico coverage of RV strains to enhance anchoring of both candidate DNAzymes to nonlooped genomic viral RNA. Additionally, the right (59) binding domains were prolonged to strengthen their interaction with the looped viral RNA sequence on anchoring of the left binding domain to nonlooped RNA. This strategy led to a huge semiquantitative improvement in cleavage activity of Dua-1 (Fig 2) and Dua-2 (Fig 3) , proving that the abovementioned speculations were correct.
Testing of DNAzyme candidates with shortened binding domains, which was conducted as an additional control procedure, completely abolished any enzymatic activity (Figs 2 and 3) . Further fine tuning of Dua-1 and Dua-2 conducted with a quantitative approach made it possible to shorten the left binding domain of both candidate DNAzymes by one nucleotide without Cleaving activity (semiquantitatively): 1, weak; 11, moderate; 111, strong; 1111, excellent. DNAzyme candidates were tested only with strains for which they were designed (some candidate DNAzymes were designed against more strains in case of full homology). Otherwise, an empty space is left. àPercentages were calculated, taking into account only published RV genomic sequences with known genomic sequence for the region of candidate DNAzyme target cleavage site. As a result, the total amount of published RV genomic sequences referred to differs depending on the target motif of the tested DNAzyme candidate. Cleaving activity (semiquantitatively): +, weak; ++, moderate; +++, strong; ++++, excellent; 2, none. DNAzyme candidates were tested only with strains for which they were designed (some candidate DNAzymes were designed against more strains in case of full homology). Otherwise, an empty space is left. àBecause of the differing and partly unknown location of CREs in different RV species, further analysis for possible sequencing gaps, particularly noncovered sequences, was not carried out. As a result, percentages refer to the total number of 322 published RV genomic sequences.
any loss in cleavage efficiency (Fig 4 and see Fig E2 in this article's Online Repository at www.jacionline.org), at the same time increasing the chance for them to quickly dissociate from RNA after the cleavage. It turned out that the presence of guanine after 3 adenines at the 59 end was critical for efficient binding of the left arm to viral RNA in case of both candidate DNAzymes. Nevertheless, longer variants were tested in those experiments, but they showed similar cleavage efficiency and were thus excluded from further investigation (Fig 4 and see Fig E2) .
As a result, Dua-1-L12R9 and Dua-2-L10R11 were discovered as the best DNAzyme candidate molecules also offering very good RNA cleavage activity (Fig 4 and see Fig E2) and broad in silico coverage of more than 98% RV strains. Those 2 molecules were followed in further experimental work. Tables I and II , the Methods section, and the online-only material in this article's the Online Repository at www.jacionline.org.
Exclusion of cytotoxic and off-target effects of Dua-1-L12R9 and Dua-2-L10R11
TLR9 preferentially expressed by innate immune cells recognizes single-stranded DNA containing unmethylated CpG motifs, which leads to stimulation of the cells reflected by activation of the NF-kB pathway. 48 DNAzymes of the 10-23 family contain such a motif in their catalytic domain, and further CpG motifs might be present in the binding domains, which is indeed the case for Dua-1-L12R9 and Dua-2-L10R11.
HEK293 cells stably transfected with either mouse or human TLR9 expression plasmids and a NF-kB-luciferase reporter system were exposed to increasing concentrations of Dua-1-L12R9 and Dua-2-L10R11 to determine whether these 2 DNAzymes can lead to TLR9-mediated cell stimulation. 22, 33 The potential cellular toxicity of Dua-1-L12R9 and Dua-2-L10R11 was also investigated.
Unlike the reference oligonucleotides known to stimulate mouse or human TLR9, thus serving as positive controls, Dua-1-L12R9 and Dua-2-L10R11 did not lead to NF-kB activation mediated through mouse (Fig 5, A) or human (Fig 5, B) TLR9. Simultaneously, neither Dua-1-L12R9 nor Dua-2-L10R11 affected cell viability (Fig 5, C and D) . Thus both candidate anti-RV DNAzymes demonstrated comparably favorable offtarget/cytotoxic profiles, and we focused on Dua-1-L12R9 in subsequent investigations. cells was used, with subsequent TCID 50 in Ohio HeLa cells as the readout, to test the antiviral effectiveness of Dua-1-L12R9 on the level of RV infection in living cells. [34] [35] [36] The efficiency of candidate or control DNAzyme transfection was previously optimized and then controlled with a FAM-labelled unrelated DNAzyme and confocal laser-scanning fluorescence microscopy. 18, 20, 23 BEAS-2B cells first infected with RVA1, RVA16, or RVA29 and then chemically transfected with Dua-1-L12R9 (Fig 6, A) demonstrated significantly lower viral titers compared with cells transfected with any control, including 2 scrambled control DNAzymes and untransfected cells (Fig 6, B-D) . In case of RVA29, the differences were slightly weaker than those observed for RVA1 or RVA16, which most probably resulted from the generally lower titers it produced, proportionally reducing also the magnitude of the observed anti-RV effect (Fig 6, B-D) .
Anti-RV efficiency in human sinonasal tissue. Antiviral efficiency of Dua-1-L12R9 was then tested in sinonasal tissues obtained from patients with CRSwNP in a unique and validated explant ALI-culture-based system, 38, 39 which was previously studied in the context of experimental DNAzyme treatment. 20 DNAzyme tissue penetration efficiency was verified by using an FAM-labeled unrelated DNAzyme and confocal laser scanning microscopy. 18, 20, 23 In addition, for the purposes of the present study, viral titers required for an effective and robust infection of epithelial cells were established in preceding experiments involving validation with immunofluorescence staining. Viral copy numbers were ascertained by using a validated realtime PCR method, as previously described. 40 Sinonasal tissue samples were first infected with RVA16 and then incubated with Dua-1-L12R9, 2 different scrambled control DNAzymes, or TCM only (Fig 7, A) . As shown in Fig 7, B, samples treated with Dua-1-L12R9 showed significantly lower copy numbers than those transfected with the 2 controls mentioned above.
Overall, Dua-1-L12R9 was found to efficiently reduce RV load/infection in the human bronchial epithelial cell line and ex vivo-cultured human sinonasal tissue.
DISCUSSION
Because of their causal contribution to common colds, to exacerbations of asthma and COPD, and possibly to asthma development, [2] [3] [4] [5] [6] [7] 9, [49] [50] [51] [52] [53] [54] [55] [56] RVs represent a thus far unmet health and economic problem. There is currently neither a clinically available drug specifically targeting RV infections nor an effective anti-RV vaccine available, which is not surprising considering several RV-specific aspects that make the development of a really useful anti-RV drug or vaccine difficult. Despite considerable homology between multiple RV strains in certain genomic RNA regions, differences between strains are substantial enough to make the design of a universal drug or a vaccine against RVs rather complicated. 7, [14] [15] [16] 25 Universality (ie, the ability of the potential anti-RV medicine to target infections evoked by all or almost all RV strains) is certainly a prerequisite here. In subjects at risk of disease exacerbation, an effective anti-RV therapy needs to be applied immediately after symptom onset or even suspicion of an infection. However, because local tissue spreading of the virus occurs rapidly, there is no time to identify the viral strain ahead of applying a strain-specific antiviral therapy. Therefore the development of a global anti-RV therapy is needed. Considering the high incidence of casual RV infections, it needs to be mentioned here that not all cases of RV infection require specific antiviral treatment, such as RV infections resulting in typical upper respiratory tract symptoms of common cold in otherwise healthy subjects.
The aim of this work was to create a DNAzyme-based anti-RV drug candidate capable of being specifically efficient against as many as possible (optimally all) RV types. DNAzymes are antisense technology-based molecules 21, 22, [27] [28] [29] specifically binding and cleaving targeted RNA molecules. We designed and then tested candidate DNAzymes against potential cleavage sites in 2 regions of the RV genomic RNA originally expected (Fig 5, A) TLR9-mediated activation in HEK293 cells line stably transfected with a construct expressing mouse TLR9 and an NF-kB-luciferase reporter. Testing for human (Fig 5, B) TLR9-mediated activation was conducted similarly; only purchased HEK cells expressing human TLR9 were used along with the compatible readout system. Murine or human CpG motif-containing oligonucleotides (ODN 1668 and ODN 2006, respectively) served as positive controls for TLR9-mediated activation. NF-kB activation with 30 mmol/L ODN 1668 (Fig 5, A) or ODN 2006 (Fig 5, B) was considered as 100% signal. No relevant murine or human TLR9-mediated activation of NF-kB was observed, except if exerted by specific positive controls. Simultaneously, cell viability was tested in mouse (Fig 5, C) and human (Fig 5, D) TLR9 stimulation HEK-based systems. In both cases untreated cells served as controls (100% viable cells). No effect of tested oligonucleotides on cell viability was observed in either test system. Data are shown as means with SEMs.
by us to inherit a sufficiently high homology between strains, namely 59-UTR and CRE. 15, 25, 41 In combination with bioinformatic analysis of the genomic sequences of known RV strains, 14 a number of DNAzyme candidates could be identified in the initial screening phase of the study, showing either strong in vitro cleavage activity or, by a full reverse complementarity, a potential to target multiple RV types in silico. Unfortunately, we did not identify molecules directly combining the 2 characteristics during this phase.
We managed this problem by extending the binding arms of Dua-01 and Dua-02, 2 DNAzyme candidates rather weakly cleaving but being fully reverse complementary to more than 98% of known RV strains. This modification substantially improved the catalytic efficacy of both tested molecules, confirming our hypothesis that the efficiency of the original not yet prolonged Dua-01 and Dua-02 was limited by poor accessibility of the target RNA resulting from the presence of the secondary structure in the region. 24 It is noteworthy that this efficacy was observed under conditions closely mimicking intracellular electrolyte composition, mainly considering concentrations of Mg 21 , an ion that serves as an essential cofactor for DNAzyme catalytic activity. 30, 57 At the same time, their ability to target 98% of RV types remained unaffected.
Subsequent testing for cellular toxicity and off-target effects demonstrated favorable profiles for both Dua-2-L10R11 and Dua-1-L12R9. Absence of toxicity can possibly be attributed to the natural composition of tested candidate DNAzymes consisting of unmodified nucleotides. 17 Only 1 thymidine was added as an inverted nucleotide to the sequences to stabilize them in biological systems by impeding exonuclease degradation. 17, 30, 31 This modification was successfully used by us in the previous studies on the anti-GATA3 DNAzyme. [18] [19] [20] [21] [22] [23] Thereafter, Dua-1-L12R9 was studied for its anti-RV efficiency in human bronchial epithelial cells and in ex vivo ALI-cultured human sinonasal tissue. In both of these test systems, application of Dua-1-L12R9 after RV infection led to significantly lower viral loads compared with the relevant controls.
Although it goes beyond the scope of the present study, additional in silico analyses (data not shown) conducted by us demonstrated that the binding domains of Dua-1-L12R9 are fully (Fig 6, B) , RVA16 (Fig 6, C) , and RVA29 (Fig 6, D) reverse complementary to genomic RNA of not only RVs but also other members of the genus Enterovirus. Dua-1-L12R9 shows a very good coverage of ''human'' (Enterovirus A-D species; comprising coxsackieviruses, human and simian enteroviruses, polioviruses, and echoviruses) and a partial coverage of ''animal'' (Enterovirus E-J species) members of the genus. 58, 59 Thus Dua-1-L12R9 can be efficient also against these pathogens. Moreover, the extremely high homology of the RNA genome region targeted by Dua-1-L12R9 not only among RVs but also among other members of the genus Enterovirus suggests that this particular sequence is absolutely crucial for the functionality of the RNA genome in those viruses, with not even single nucleotide changes allowed. As a result, there is only a minimal chance that mutations develop in this region creating potential resistance against Dua-1-L12R9 treatment. 60, 61 Even though direct anti-RV strategies have also been investigated quite intensively, successful causative approaches are still missing. The large number of RV strains with varying antigen repertoires makes it difficult to develop a clinically useful anti-RV vaccine. Unfortunately, recent reports demonstrated that inactivated RV vaccines are rather RV type specific and not cross-neutralizing. 62 In addition, even though RV antibody responses can have a weak cross-neutralization potential in animals, they seem mostly misdirected to internal epitopes in human subjects. [63] [64] [65] [66] Data obtained in mice and macaques suggest that a very highly polyvalency (against 25-50 virus types or maybe even more) is required to enable for development of an effective anti-RV vaccine. 54, 62 In addition, several chemical compounds with anti-RV potential have been invented [67] [68] [69] ; however, none of these made it into the clinics thus far. 65, 67, 68 Some are still under clinical evaluation, such as the capsid binders pleconaril or vapendavir (BTA798), 68 the major drawback of which is the rapid emergence of resistance. 65, 68 Finally, several antisense technology-based drug development studies attempting to create candidate therapeutics directly targeting RV infection were reported 10 or more years ago [70] [71] [72] [73] ; however, none of those molecules has ever entered clinical trials. 17, 74 Early or even preventive management of RV infections can reduce the incidence of common colds, asthma/COPD exacerbations, and possibly childhood asthma development. We created a series of potential DNAzymes, with the lead candidate Dua-1-L12R9 efficiently targeting almost all RVs. These results are encouraging for further preclinical development (ie, animal studies and then, hopefully, clinical trials). 
